

1 **Review Protocol**

2 Oral ulcers of COVID-19 patients: a scoping review protocol

3 **Author(s)**

4 Abanoub RIAD,^{1,2,†} Julien ISSA,^{3,†} Veronika CHUCHMOVA,² Esraa GOMAA,⁴ Andrea POKORNA,^{1,5} Jitka
5 KLUGAROVA,^{1,2} Miloslav KLUGAR^{1,2}

6 **Affiliation(s)**

7 ¹ Czech National Centre for Evidence-Based Healthcare and Knowledge Translation (Cochrane Czech
8 Republic, Czech EBHC: JBI Centre of Excellence, Masaryk University GRADE Centre), Institute of
9 Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic

10 ² Department of Public Health, Faculty of Medicine, Masaryk University, Brno, Czech Republic

11 ³ Department of Esthetic and Restorative Dentistry, Faculty of Dentistry, Saint Joseph University,
12 Beirut, Lebanon

13 ⁴ Department of Oral Medicine and Oral Radiology, Faculty of Dentistry, Egyptian Russian University,
14 Cairo, Egypt

15 ⁵ Department of Nursing and Midwifery, Faculty of Medicine, Masaryk University, Brno, Czech
16 Republic

17 **Corresponding Author**

18 Dr. Abanoub RIAD, DDS

19 **P.O.:** Czech National Centre for Evidence-Based Healthcare and Knowledge Translation (Cochrane
20 Czech Republic, Czech EBHC: JBI Centre of Excellence, Masaryk University GRADE Centre), Institute
21 of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00, Brno,
22 Czech Republic

23 **Email:** abanoub.riad@med.muni.cz

24 [†] These authors contributed equally to the work.

25 **Abstract**

26 **Objective:** This scoping review aims to systematically identify the types, characteristics, and possible
27 pathophysiologic etiologies of the oral ulcers that emerge in COVID-19 patients.

28 **Introduction:** The oral cavity is a vulnerable niche for the most diverse microbial ecosystem in the
29 human body; therefore, it presents a wide array of mucocutaneous complications that could indicate
30 various acute and chronic conditions. The COVID-19-related oral conditions, including oral ulcers,
31 had been widely debated as direct manifestations or indirect complications of the SARS-CoV-2
32 infection. According to a preliminary search of PROSPERO, MEDLINE, the Cochrane Database of
33 Systematic Reviews and the *JBI Evidence Synthesis*, there is no published nor registered scoping
34 review concerned with the oral ulcers of COVID-19 patients.

35 **Inclusion criteria:** The review will include studies included COVID-19 patients whose infection had
36 been confirmed by RT-PCR testing regardless of infection severity and clinical course. Only the
37 studies that reported COVID-19 patients with oral ulcers.

38 **Methods:** A three-phase search strategy will be carried out: an initial limited search, a full electronic
39 search, and hand search using the reference lists of all included records. The main bibliographic
40 databases of published literature will include MEDLINE (PubMed), Cochrane COVID-19 Study
41 Register, EMBASE via Ovid, and Scopus. All identified records will be managed using EndNote 9.2,
42 and the titles and abstracts will be screened against the inclusion criteria before the full text of all
43 potentially relevant studies will be examined. The data will be presented in tabular form, rating
44 maps, and narrative summary.

45 **Registration:** This protocol had been pre-registered in Open Science Framework (OSF) Registries.^[1]

46 **Keywords:** Aphthous Stomatitis, COVID-19, Oral Manifestations, Oral Ulcer

47 **Abstract word count:** 244

48 **Total manuscript word count:** 1532

49 Introduction

50 The outbreak of the coronavirus disease (COVID-19) had required sensitive case definitions to be
51 developed according to the dynamically growing epidemiologic evidence.^[2] The COVID-19-related
52 extrapulmonary manifestations including the cutaneous lesions had been frequently reported since
53 the beginning of this pandemic; however, it took several months until these lesions were recognized
54 by the World Health Organization (WHO) within the clinical case definitions of COVID-19.^[2,3]
55 According to the review of Daneshgaran *et al.* 2020, the vesicular rashes were suggested to be used
56 for early diagnosis of COVID-19; while acral lesions were useful for epidemiological uses, and
57 vascular rashes for the prognosis of the disease severity.^[4]

58 The oral cavity is subjected to numerous environmental factors that make it vulnerable to
59 mucocutaneous complications. This vulnerability is supported by the fact that the oral cavity is a
60 locus of the most diverse microbial ecosystem in the human body; therefore, it can harbour
61 accessible lesions that could be diagnostic for an array of systemic conditions.^[5] Ulceration of the
62 oral epithelium, underlying connective tissues, or both may last for two weeks or more, and it can be
63 triggered by chronic conditions including drug-induced oral ulcers, lichen planus, pemphigus vulgaris,
64 mucous membrane pemphigoid, lupus erythematosus, Reiter's syndrome, tuberculosis, eosinophilic
65 ulcers, precancerous ulcers, and mycoses-related ulcers.^[6] Additionally, oral ulcers may be of acute
66 nature and last for less than two weeks, e.g. traumatic ulcers, recurrent aphthous stomatitis (RAS),
67 Bechet's disease, allergic reactions, erythema multiform, necrotizing sialometaplasia, hematologic
68 disorders-related ulcers, and bacterial and viral infections. The clinical presentation of some viral
69 infections like herpes simplex virus, varicella-zoster virus, coxsackievirus, cytomegalovirus,
70 Epstein-Barr virus, measles virus, and human immunodeficiency virus (HIV) includes typically oral
71 ulcers and vesicles which may aid in their timely diagnosis and management.^[7]

72 The oral symptoms of COVID-19 had been first reported in Lyon by Chaux-Bodard *et al.* 2020 as an
73 irregular tongue ulcer which evolved concurrently with acral erythema preceding the COVID-19
74 respiratory symptoms thus suggesting a promising epidemiological and clinical significance of the
75 oral lesions as inaugural symptoms.^[8] In the following weeks, hundreds of individual cases with
76 different oral lesions were reported in multiple countries to explain the nature and the aetiology of
77 these lesions, which were equally distributed in females vs males.^[9-11] The COVID-19-related oral
78 symptoms could be depicted as drug reactions, viral enanthem, stress-induced lesions, bacterial or
79 fungal co-infections, or inflammatory reaction.^[9,11] Heretofore, the pathophysiological hypotheses of

80 COVID-19-related oral symptoms are supported by collateral observations that require further
81 investigation; for instance, the hypothesis of viral enanthema is supported by the high expression of
82 angiotensin-converting enzyme-2 (ACE-2) receptors in oral epithelium which serve as the primary
83 entry of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2); also the inflammatory
84 response hypothesis is supported by the increasing number of cases of the pediatric multisystem
85 inflammatory syndrome temporally associated with SARS-CoV-2 (PMIS-TS).^[9,12] However, the onset
86 of oral lesions had considerably varied across the reported cases due to lack of use of reference
87 timepoints, it may indicate the variety of pathophysiologic etiologies and the natures of these
88 lesions.^[9]

89 The COVID-19-related oral ulcers had been reported in critically-ill,^[13,14] moderate,^[15] mild^[15-17] and
90 asymptomatic cases^[16]. Aphthous-like lesions were reported without necrosis and hemorrhagic
91 crusts in younger patients, while in older patients with severe infection, the aphthous-like lesions
92 had been necrotic and hemorrhagic.^[11] In a recent review of aphthous stomatitis in COVID-19
93 patients, the aphthous lesions were slightly predominant in females and people below 40 years old,
94 and their onset ranged between 0 to 10 days since the emergence of the respiratory symptoms.^[15]
95 The tongue was the most common location for ulcerative and erosive lesions of non-specific origin
96 which appeared 3 days before the onset of respiratory symptoms in one of the cases.^[11] Herpetiform
97 lesions were painful and emerged before, during, or after the respiratory symptoms.^[11]

98 This scoping review's primary objectives are to evaluate the breadth and depth of the evidence on
99 oral lesions of COVID-19 patients and to evaluate their proposed pathophysiological courses and
100 epidemiological and clinical significance. A preliminary search of PROSPERO, MEDLINE, the Cochrane
101 Database of Systematic Reviews and the *JBI Evidence Synthesis* was conducted on January 20th, 2020,
102 and no current or underway scoping reviews or systematic reviews on the topic were identified.

103 **Review question(s)**

104 What are the possible etiologies, types, and characteristics of the oral ulcers that emerge in
105 COVID-19 patients?

106 **Inclusion criteria**

107 *Participants*

108 This review will consider studies that include COVID-19 patients whose infection had been confirmed

109 by means of RT-PCR.

110 *Concept*

111 This review will consider studies that reported any type of oral ulcers for example: solitary vs.
112 multiple, acute vs. recurrent, painful vs. painless, necrotic vs. non-necrotic, hemorrhagic vs.
113 non-hemorrhagic, or contagious vs. non-contagious.

114 *Context*

115 This review will consider studies that reported COVID-19 patients with mild, moderate, severe and
116 critic clinical courses according to the Australian guidelines for clinical care of COVID-19 patients.^[18]
117 The patients hospitalized either at intensive care or intermediate care (which provides more
118 intensive monitoring and patient management than the general ward but less than is offered in the
119 intensive care),^[19] and the patients who underwent home isolation will be included in this review.

120 *Types of sources*

121 This scoping review will consider descriptive as well as analytical epidemiological studies.
122 Furthermore, systematic reviews, narrative reviews and correspondence articles will be considered
123 for inclusion in the proposed scoping review.

124 **Methods**

125 The proposed scoping review will be conducted in accordance with the JBI methodology for scoping
126 reviews.^[20]

127 *Search strategy*

128 The search strategy will locate both published and unpublished primary studies, reviews, and
129 correspondence articles. A three-phase search strategy will be carried out. The first phase, which has
130 been already completed, was an initial limited search of MEDLINE (PubMed) and Google Scholar to
131 identify relevant articles, followed by an analysis of the text words contained in the titles and
132 abstracts of retrieved records, in addition to the index terms used to describe these records. A full
133 search strategy for MEDLINE (PubMed) is stipulated in [Appendix 1](#). Secondly, the search strategy will
134 be developed according to the previous phase using all identified keywords and index terms, and it
135 will be customized for each included information source. Finally, the bibliographical reference lists of

136 all the included records will be screened for additional records.

137 Only studies published in English will be included. All the studies published since January 1st, 2020
138 will be included as the first cluster of COVID-19 cases was reported in Wuhan, China on December
139 30th, 2019.

140 **Information sources**

141 The databases to be searched include: MEDLINE (PubMed), Cochrane COVID-19 Study Register,
142 EMBASE via Ovid, and Scopus. The search for unpublished studies and gray literature will include:
143 medRxiv, ClinialTrials.gov, and the WHO's International Clinical Trials Registry Platform (ICTRP)
144 through the Cochrane COVID-19 Study Register [Clinicians working with COVID-19 patients].

145 *Study selection*

146 Following the search, all identified records will be collated and uploaded into EndNote 9.2 (Clarivate
147 Analytics, PA, USA) and duplicates removed. Following a pilot test, titles and abstracts will then be
148 screened by two independent reviewers (A.R. and J.I.) against the inclusion criteria. The potentially
149 relevant records will be retrieved in full and their citation details imported into the JBI System for
150 the Unified Management, Assessment and Review of Information (JBI SUMARI; JBI, Adelaide,
151 Australia).^[21] The full text of the selected records will be assessed in detail against the inclusion
152 criteria by two independent reviewers (A.R. and J.I.). Reasons for exclusion of full-text records that
153 do not meet the inclusion criteria will be recorded and reported in the scoping review. Any
154 disagreements that arise between the reviewers at each stage of the selection process will be
155 resolved through discussion or with a third reviewer (M.K.). The search results will be reported in full
156 in the final scoping review and presented in a Preferred Reporting Items for Systematic Reviews and
157 Meta-analyses for Scoping Reviews (PRISMA-ScR) flow diagram.^[22]

158 *Data extraction*

159 Data will be extracted from records included in the scoping review by two independent reviewers
160 (A.R. and J.I.) using a draft charting form developed by the reviewers. The team will trial the charting
161 form to ensure that all relevant results are extracted, and the table will be revise and amended
162 when required during the data charting process. Modifications will be detailed in the full scoping
163 review. Any disagreements that arise between the reviewers will be resolved through discussion or

164 with a third reviewer. The primary studies' authors will be contacted to request missing or additional
165 data, where required. The data extracted will include specific details such as author(s), year of
166 publication, country (where the cases were reported), study design, study population (age and
167 gender), medical history, COVID-19 symptoms, ulcer characteristics (color, size, number, location,
168 onset, and duration) and treatment. A draft extraction tool is provided (see [Appendix 2](#)).

169 *Data analysis and presentation*

170 The extracted data will be presented in tabular form according to the objectives of this scoping
171 review. Additionally, rating maps will be used to display the frequency of reported cases. The
172 tabulated results will be accompanied by a narrative summary demonstrating how the results relate
173 to the scoping review's objectives.

174 **Ethical consideration**

175 The ethical committee of Masaryk University – Faculty of Medicine has exempted this study from
176 getting approval due to the fact that it uses open-access data.

177 **Conflicts of interest**

178 The authors declare no conflict of interest.

179 **Funding statement**

180 Masaryk University supported the work of A.R. and V.C. by the grants MUNI/A/1608/2020 and
181 MUNI/IGA/1543/2020. The work of A.R., A.P. J.K. and M.K. was supported by the INTER-EXCELLENCE
182 grant number LTC20031 – “Towards an International Network for Evidence-based Research in
183 Clinical Health Research in the Czech Republic”.

184 **Data availability statement**

185 The data that support the findings of this study are openly available in Open Science Framework at
186 <https://doi.org/10.17605/OSF.IO/JWAU4>

187 **References**

- 188 1. Riad A, Issa J, Chuchmova V, Gomaa E, Pokorna A, Klugarova J, et al. Oral ulcers of COVID-19
189 patients: a scoping review protocol [Internet]. Open Science Framework (OSF) Registeries.
190 2021 [cited 2021 Jan 22]. Available from: <https://osf.io/jwau4>

- 191 2. World Health Organization (WHO). Coronavirus disease (COVID-19) [Internet]. [cited 2021 Jan
192 20]. Available from:
193 <https://www.who.int/news-room/q-a-detail/coronavirus-disease-covid-19>
- 194 3. Wollina U, Karadağ AS, Rowland-Payne C, Chiriac A, Lotti T. Cutaneous signs in COVID-19
195 patients: A review [Internet]. Vol. 33, *Dermatologic Therapy*. Blackwell Publishing Inc.; 2020
196 [cited 2021 Jan 20]. Available from: </pmc/articles/PMC7273098/?report=abstract>
- 197 4. Daneshgaran G, Dubin DP, Gould DJ. Cutaneous Manifestations of COVID-19: An
198 Evidence-Based Review [Internet]. Vol. 21, *American Journal of Clinical Dermatology*. Adis;
199 2020 [cited 2021 Jan 20]. p. 627–39. Available from:
200 <https://doi.org/10.1007/s40257-020-00558-4>
- 201 5. Chi AC, Neville BW, Krayer JW, Gonsalves WC. Oral Manifestations of Systemic Disease
202 [Internet]. Vol. 82, *American Family Physician*. 2010 Dec [cited 2021 Jan 20]. Available from:
203 www.aafp.org/afpAmericanFamilyPhysician
- 204 6. Muñoz-Corcuera M, Esparza-Gómez G, González-Moles MA, Bascones-Martínez A. Oral
205 ulcers: clinical aspects. A tool for dermatologists. Part II. Chronic ulcers. *Clin Exp Dermatol*
206 [Internet]. 2009 Jun 1 [cited 2021 Jan 20];34(4):456–61. Available from:
207 <http://doi.wiley.com/10.1111/j.1365-2230.2009.03219.x>
- 208 7. Muñoz-Corcuera M, Esparza-Gómez G, González-Moles MA, Bascones-Martínez A. Oral
209 ulcers: clinical aspects. A tool for dermatologists. Part I. Acute ulcers. *Clin Exp Dermatol*
210 [Internet]. 2009 Apr 1 [cited 2021 Jan 20];34(3):289–94. Available from:
211 <http://doi.wiley.com/10.1111/j.1365-2230.2009.03220.x>
- 212 8. Chauv-Bodard AG, Deneuve S, Desoutter A. Oral manifestation of Covid-19 as an inaugural
213 symptom? [Internet]. Vol. 26, *Journal of Oral Medicine and Oral Surgery*. EDP Sciences; 2020
214 [cited 2020 Nov 25]. p. 18. Available from: <https://doi.org/10.1051/mbcb/2020011>
- 215 9. Riad A, Klugar M, Krsek M. COVID-19 Related Oral Manifestations, Early Disease Features?
216 *Oral Dis* [Internet]. 2020 Jun 30 [cited 2020 Jul 13];odi.13516. Available from:
217 <https://onlinelibrary.wiley.com/doi/abs/10.1111/odi.13516>
- 218 10. Eghbali Zarch R, Hosseinzadeh P. COVID-19 from the perspective of dentists: A case report
219 and brief review of more than 170 cases. *Dermatol Ther* [Internet]. 2021 Jan [cited 2021 Jan

- 21]; Available from: <https://onlinelibrary.wiley.com/doi/10.1111/dth.14717>
- 221 11. Iranmanesh B, Amiri R, Zartab H, Aflatoonian M. Oral manifestations of COVID-19 disease: A
222 review article. *Dermatol Ther [Internet]*. 2020 Nov 25 [cited 2020 Dec 8];dth.14578. Available
223 from: <https://onlinelibrary.wiley.com/doi/10.1111/dth.14578>
- 224 12. Riad A, Boccuzzi M, Sagiroglu D, Klugar M, Krsek M. Pediatric multisystem inflammatory
225 syndrome temporally associated with SARS-COV-2: Oral manifestations and implications. *Int J*
226 *Paediatr Dent [Internet]*. 2020 Aug 21 [cited 2020 Aug 30];jpd.12694. Available from:
227 <https://onlinelibrary.wiley.com/doi/abs/10.1111/ipd.12694>
- 228 13. Amorim dos Santos J, Normando AGC, Carvalho da Silva RL, De Paula RM, Cembranel AC,
229 Santos-Silva AR, et al. Oral mucosal lesions in a COVID-19 patient: New signs or secondary
230 manifestations? [Internet]. Vol. 97, *International Journal of Infectious Diseases*. Elsevier B.V.;
231 2020 [cited 2020 Dec 10]. p. 326–8. Available from:
232 <https://pubmed.ncbi.nlm.nih.gov/32526392/>
- 233 14. Brandão TB, Gueiros LA, Melo TS, Prado-Ribeiro AC, Nesrallah ACFA, Prado GVB, et al. Oral
234 lesions in patients with SARS-CoV-2 infection: could the oral cavity be a target organ? *Oral*
235 *Surg Oral Med Oral Pathol Oral Radiol [Internet]*. 2020 Aug 18 [cited 2020 Dec 12]; Available
236 from: [/pmc/articles/PMC7434495/?report=abstract](https://pubmed.ncbi.nlm.nih.gov/32526392/)
- 237 15. Riad A, Kassem I, Stanek J, Badrah M, Klugarova J, Klugar M. Aphthous Stomatitis in COVID-19
238 Patients: Case-series and Literature Review. *Dermatol Ther [Internet]*. 2021 Jan 3 [cited 2021
239 Jan 3]; Available from: <https://onlinelibrary.wiley.com/doi/10.1111/dth.14735>
- 240 16. Riad A, Kassem I, Hockova B, Badrah M, Klugar M. Tongue ulcers associated with SARS-CoV-2
241 infection: A case series. *Oral Dis [Internet]*. 2020 Sep 25 [cited 2021 Jan 13];odi.13635.
242 Available from: <https://onlinelibrary.wiley.com/doi/10.1111/odi.13635>
- 243 17. Al-Khanati NM, Riad A, Sahloul ME, Klugar M. Aphthous-like stomatitis of COVID-19 patients.
244 *Brazilian J Oral Sci [Internet]*. 2020 Nov 4 [cited 2020 Dec 4];19:e201354–e201354. Available
245 from: <http://dx.doi.org/10.20396/bjos.v19i0.8661354>
- 246 18. NHMRC NH and MRC. Australian Guidelines for the clinical care of people with COVID-19
247 [Internet]. *Australian Clinical Practice Guidelines*. 2020 [cited 2020 Sep 17]. Available from:
248 <https://www.clinicalguidelines.gov.au/register/australian-guidelines-clinical-care-people-covi>

- 249 d-19
- 250 19. Vincent JL, Rubenfeld GD. Does intermediate care improve patient outcomes or reduce costs?
251 Crit Care [Internet]. 2015 Mar 2 [cited 2021 Jan 23];19(1):89. Available from:
252 <http://ccforum.com/content/19/1/89>
- 253 20. Peters M, Godfrey C, McInerney P, Baldini Soares C, Khalil H, Parker D. JBI Manual for
254 Evidence Synthesis [Internet]. JBI Manual for Evidence Synthesis. JBI; 2020 [cited 2021 Jan
255 21]. Available from: <https://wiki.jbi.global/display/MANUAL>
- 256 21. Munn Z, Aromataris E, Tufanaru C, Stern C, Porritt K, Farrow J, et al. The development of
257 software to support multiple systematic review types: The Joanna Briggs Institute System for
258 the Unified Management, Assessment and Review of Information (JBI SUMARI). Int J Evid
259 Based Healthc [Internet]. 2019 Mar 1 [cited 2021 Jan 22];17(1):36–43. Available from:
260 <https://pubmed.ncbi.nlm.nih.gov/30239357/>
- 261 22. Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for
262 scoping reviews (PRISMA-ScR): Checklist and explanation [Internet]. Vol. 169, Annals of
263 Internal Medicine. American College of Physicians; 2018 [cited 2021 Jan 22]. p. 467–73.
264 Available from: <https://pubmed.ncbi.nlm.nih.gov/30178033/>

265 **Appendix I: Search strategy**

266 **MEDLINE (PubMed)**

267 Search conducted on January 22nd, 2021, from (01.01.2020) to present.

Search	Query	Records retrieved
#1	COVID-19[all] OR SARS-CoV-2[all] OR 2019-nCoV[all] OR severe acute respiratory syndrome[all] OR coronavirus[all] OR corona virus[all]	119,920
#2	Ulcer*[all] OR aphthous[all] OR herpe*[all] OR blister*[all] OR eruption*[all] OR erosion*[all] OR lesion*[all] OR vesicle*[all] OR stomatitis[all]	1,472,960
#3	Oral[all] OR mouth[all] OR tongue[all] OR lip*[all] OR labial[all] OR buccal[all] OR perioral[all] OR palate[all] OR pharyn*[all]	1,271,073
#4	#1 AND #2 AND #3	219
Limited to the date range from (01.01.2020) to present		126

268 **Appendix II: Data extraction instrument**

Author, Date, Location	Number of patients	Gender	Age	Medical anamnesis	COVID-19 symptoms	COVID-19 treatment	Ulcer characteristics				Ulcer Treatment
							Location	Number / Size	Necrosis / Hemorrhage	Onset / Duration	

269